Emergence of resistance to fosfomycin used as adjunct therapy in KPC Klebsiella pneumoniae bacteraemia: report of three cases 
Case 2
A patient with acute myelogenous leukaemia developed profound neutropenia (absolute neutrophil count ,100/mL) and new onset of fever after chemotherapy. The patient was started empirically on meropenem (2 g three times daily) and gentamicin (240 mg once daily). Blood culture grew KPC-Kp (isolate 2) that was resistant to all antimicrobials tested, except for colistin, gentamicin, tigecycline and fosfomycin (MICs 0.125, ≤4, 0.75 and 32 mg/L, respectively); the MIC of meropenem was 8 mg/L. The patient was severely septic and colistin (150 000 IU/kg/day in two divided doses) was added to the above antimicrobial regimen. Five days later, the symptoms had not improved and blood culture remained positive for KPC-Kp. Meropenem was then replaced by fosfomycin (8 g three times daily). The patient's condition partially improved and bacteraemia was cleared. Eleven days after initiation of fosfomycin and while the patient was on colistin, gentamicin and fosfomycin, fever (.388C) and bacteraemia with KPC-Kp reappeared.
The new isolate exhibited high-level resistance to fosfomycin and meropenem (MICs .1024 and .32 mg/L, respectively) while remaining susceptible to colistin, gentamicin and tigecycline (isolate 2F). The patient died 8 days later with polymicrobial bacteraemia caused by KPC-Kp, Enterococcus faecium and Candida albicans.
Case 3
A kidney transplant recipient was transferred to the intensive care unit (ICU) after cardio-respiratory arrest. On the 15th day in the ICU, the patient developed bacteraemia with KPC-Kp (isolate 3). At that time, the patient was being mechanically ventilated and receiving continuous renal replacement therapy. The isolate was susceptible only to fosfomycin (MIC 12 mg/L) and gentamicin (MIC ≤4 mg/L). The MICs of colistin, tigecycline and meropenem were 4, 3 and 8 mg/L, respectively. Treatment with gentamicin (160 mg once daily), meropenem (1 g twice daily) and fosfomycin (3 g three times daily) was initiated. After transient relief of symptoms and control of bacteraemia, fever and bacteraemia recurred and the patient died of septic shock 11 days later. The KPC-Kp blood isolate exhibited several-fold higher MICs to fosfomycin (128 mg/L), gentamicin (8 mg/L) and meropenem (.32 mg/L) (isolate 3F).
For each of the case-patients, the fosfomycin-resistant KPC-Kp isolates recovered after fosfomycin treatment were most likely mutants of the pre-treatment isolates, as indicated by PFGE typing of XbaI-digested genomic DNA. Also, all PFGE patterns were similar (.90%) to those of the KPC producers of the sequence type 258 (ST258). 3 Fosfomycin is known for its ability to readily select resistant mutants. 4 Yet, in vitro studies have indicated that its combination with colistin, gentamicin or meropenem prevents the emergence of fosfomycin-resistant K. pneumoniae variants. 5 The three cases we report cast doubts regarding the capability of combination regimens to avert the in vivo development of resistance to fosfomycin in KPC-Kp. It must be pointed out, however, that the parental isolates were not fully susceptible to all the partner drugs, which may partly explain the rapid occurrence of fosfomycin resistance.
Moreover, fosfomycin-resistant variants exhibited higher b-lactam MICs than their parental isolates (Table 1) . To reproduce this phenomenon in vitro, suspensions (10 7 cfu/mL) of isolates 1, 2 and 3 were grown in Mueller -Hinton agar containing glucose-6-phosphate (25 mg/L) and fosfomycin (100 mg/L). Stable, one-step fosfomycin-resistant mutants (MICs .1024 mg/L) were obtained at frequencies of 1×10 26 to 5×10
26
. Similar to the clinical isolates derived after fosfomycin treatment, the in vitro mutants exhibited elevated MICs of b-lactams (data not shown). Activity of non-b-lactams was not affected. Attempts to elucidate the mechanism(s) involved in the reduction of b-lactam activity were not successful. Spectrophotometric determination of total b-lactamase and carbapenemase activities of cell extracts and SDS-PAGE of outer membrane proteins 6 did not reveal differences between the clinical isolates and the respective fosfomycin-resistant mutants selected either in vivo or in vitro. The concomitant increase in b-lactam resistance (a fact that, to our knowledge, is reported here for the first time among fosfomycinresistant enterobacteria) should be investigated further. It must be noted, however, that the study concerned isolates of a single lineage (ST258). Therefore, the above observations may reflect a clonal characteristic.
Although the addition of fosfomycin as adjunct therapy to other active agents resulted in relief of symptoms and control of bacteraemia in patients with KPC-Kp infections, this effect was transient and was followed by clinical and microbiological relapse due to rapid selection of resistant variants. Additional data are required to determine the benefit from the administration of fosfomycin, if any, in the treatment of infections caused by KPC-Kp.
Sir, Drug-drug interactions (DDIs) between antiretroviral drugs (ARVs) are often complex and difficult to anticipate. The approval of ARVs, such as maraviroc and etravirine, for possible use in nucleos(t)ide reverse transcriptase inhibitor (NRTI)-or ritonavirboosted protease inhibitor (PI/r)-sparing strategies, is often ahead of DDI knowledge. The clinical implications of such DDIs in a growing population of ageing and poly-medicated patients living with HIV are likely to be important for maintaining ARV efficacy and avoiding toxicity.
As stipulated in international regulatory guidelines, specific DDI studies showing the effects of enzymatic or efflux transporter inhibitors and inducers have been conducted in healthy subjects, but few data are available on maraviroc and etravirine in HIV-infected patients. Maraviroc, a new CCR5 antagonist, is a CYP3A4 substrate demonstrating a favourable pharmacokinetic distribution profile. 1 Etravirine, a non-nucleoside reverse transcriptase inhibitor, is a CYP3A4 inducer and designed to have a high genetic barrier to the development of resistance. 2 Regarding the respective biotransformation pathways of both ARVs, it is as yet unclear which maraviroc dose (300 or 600 mg twice daily) should be chosen in combination with etravirine without any PI/r. The objective of the present study was to determine the
